What is the fair value of Geron Corporation (NASDAQ-GERN) stock?

The current fair value estimate for Geron Corporation (NASDAQ-GERN) is $1.45. This implies an estimated upside of 11.4% versus the current market price.

Is Geron Corporation (NASDAQ-GERN) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 11.4% versus the current market price.

What is the analyst price target for NASDAQ-GERN stock?

The available analyst price target for Geron Corporation (NASDAQ-GERN) is $4.25. The analyst target implies estimated upside of 226.9%.

How is the financial health of Geron Corporation?

The current financial health read for Geron Corporation (NASDAQ-GERN) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Geron Corporation's next earnings date?

The next earnings date currently listed for Geron Corporation (NASDAQ-GERN) is November 11, 2026.

Does Geron Corporation (NASDAQ-GERN) pay dividends?

The latest available data indicates no current dividend yield for Geron Corporation (NASDAQ-GERN).

What is the market capitalization of Geron Corporation?

The current market capitalization listed for Geron Corporation is 828.8 M.

What is the enterprise value of Geron Corporation?

The current enterprise value listed for Geron Corporation is 651.8 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Geron Corporation?

The ticker symbol for Geron Corporation is NASDAQ-GERN, and the stock is listed on NASDAQ.

Where is Geron Corporation (NASDAQ-GERN) listed?

Geron Corporation (NASDAQ-GERN) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Geron Corporation?

The current debt-to-total-capital ratio listed for Geron Corporation is 12.6%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Geron Corporation?

The free float listed for Geron Corporation is 86.6%. Free float helps investors understand how much of the share base is available for public trading.

Geron Corporation (GERN) Fair Value & Stock Analysis

Geron Corporation (GERN)

Geron Corporation is a commercial-stage biopharmaceutical company focused on oncology therapeutics. Its lead product is RYTELO, a telomerase inhibitor approved for adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company also has several clinical-stage programs in development, including IMerge in Phase 3 for lower-risk myelodysplastic syndromes, IMpactMF in Phase 3 for relapsed or refractory myelofibrosis, Impress in Phase 2 for higher-risk myelodysplastic syndromes and acute myeloid leukemia, IMproveMF in Phase 1 for frontline myelofibrosis, and IMAGINE in Phase 1/2 for relapsed or refractory AML. Incorporated in 1990, Geron is headquartered in Foster City, California, and its common stock trades on the NASDAQ under the symbol GERN.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-GERN	$1.45	11.4% Upside	Fair	$4.25	226.9% Upside	Bargain	Good	0.0%	November 11, 2026	3.9x	4.2x	828.8 M	651.8 M	12.6%	86.6%	-2.2	169.7%